Shares of Amgen Inc. AMGN inched 0.24% higher to $264.00 Monday, on what proved to be an all-around favorable trading session ...

Amgen's leukemia drug Blincyto infringes patents owned by Germany's Lindis Biotech, a Delaware federal jury said in a verdict ...

Shares of Amgen Inc. AMGN slumped 0.21% to $265.95 Tuesday, on what proved to be an all-around dismal trading session for the ...

We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options ...

StockNews.com lowered shares of Amgen (NASDAQ:AMGN – Free Report) from a strong-buy rating to a buy rating in a research ...

Amgen Inc (AMGN) stock saw a modest uptick, ending the day at $263.38 which represents a slight increase of $2.19 or 0.84% from the prior close of $261.19. The stock opened at $269 and touched a low ...

Novo Nordisk's CagriSema shows 22.7% weight loss in Phase 3 trials, while tolerability concerns grow. MariTide offers ...

Novo Nordisk stock crashed Friday after the firm's next-generation weight-loss drug missed expectations in a highly ...

We recently compiled a list of the 10 Dogs of the Dow Dividend Stocks to Invest in. In this article, we are going to take a ...

We recently compiled a list of the 12 Best Weight Loss Stocks to Buy According to Hedge Funds. In this article, we are going ...

The most recent trading session ended with Amgen (AMGN) standing at $264, reflecting a +0.24% shift from the previouse trading day's closing. This move lagged the S&P 500's daily gain of 0.73%.

BeiGene has struck a $150 million deal to license a cancer candidate from CSPC Zhongqi Pharmaceutical Technology, positioning ...